Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

ElixaMD vs Somira Health

ElixaMD
Graded #257

Higher grade

vs+1.2999999999999972
Somira Health
Graded #278

Lower grade

The verdict

ElixaMD takes it — 63.5/100 to 62.2/100, but only just.

ElixaMD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. ElixaMD is a doctor-guided online weight-loss telehealth offering compounded semaglutide injections from $179 the first month, with free shipping, no membership, no contract, and no insurance required. Somira Health is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueSomira Health +1
50
51
Dose & formulationSomira Health +12
52
64
Clinical oversightElixaMD +15
92
77
Labs & monitoringElixaMD +1
63
62
FulfillmentSomira Health +7
76
83
Contract termsElixaMD +20
45
25
ElixaMD · left barSomira Health · right bar

The numbers

MetricElixaMDSomira Health
WeighScore63.5/10062.2/100
GradeCC
Scorecard rank#257#278
Semaglutide$179/mo (starting dose, first-month rate, compounded)$190/mo (compounded)
TirzepatideNot disclosed$285/mo (compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
ElixaMD

Graded #257 · C

Strengths

  • Compounded semaglutide from $179 first month with free shipping, no membership, no contract, and no insurance required
  • Genuinely all-inclusive: 1:1 physician guidance, free dietician visits and care coaching, 24/7 support, and an all-in-one patient portal
  • Names its compounding pharmacies (RedRock Pharmacy, Beaker Pharmacy) — more transparent than most compounded sellers
  • HSA/FSA eligible; full legal suite (Terms, Privacy, Privacy Practices, Refund, Medical Consent, California Bill of Rights)

Where it loses points

  • $179 is a first-month/intro price — ongoing monthly cost is higher (tiers to ~$249-$299)
  • Compounded semaglutide is not FDA-approved (the site discloses this) — not brand Wegovy or Ozempic
  • Appears to offer compounded semaglutide only — tirzepatide is not advertised
  • Displays a generic LegitScript Certified badge but no verifiable seal/listing; state-availability list not published
Somira Health

Graded #278 · C

Strengths

  • Transparent flat monthly pricing that does not increase as you titrate (semaglutide $189.99/mo, tirzepatide $284.99/mo)
  • Quarterly plans lower the effective monthly cost (semaglutide $136.66/mo, tirzepatide $221.66/mo)
  • Free overnight shipping, with syringes and alcohol wipes included in every order
  • Simple, fast online intake reviewed by a licensed provider; no insurance required
  • Both weekly compounded GLP-1 options offered: semaglutide and tirzepatide

Where it loses points

  • Compounded medications are not FDA-approved (the site discloses this) — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • The compounding pharmacy partner is not named
  • State-availability list is not published
  • No LegitScript certification displayed
  • New, thin platform with limited public detail on the provider network, lab monitoring, or ongoing support

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard